This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
To own Nutex Health, you need to believe its micro hospital network and arbitration driven revenue model can stay resilient while it keeps adding capacity in attractive markets. The new West Little Rock facility modestly reinforces the near term catalyst of volume growth from openings, but it does not directly reduce the biggest risk around Nutex’s reliance on the No Surprises Act arbitration process and the collection of out of network awards.
The recent second quarter 2026 earnings highlight this tension: Nutex reported US$210.75 million in revenue, down from US$243.99 million a year earlier, but net income swung to US$65.84 million from a US$17.70 million loss. For investors tracking the impact of new hospitals like West Little Rock, this mix of lower revenue with higher profitability raises questions about how much future openings versus arbitration outcomes and cost controls will drive results.
Yet beneath the expansion story, the heavier dependence on arbitration related revenue is something investors should be aware of, especially if...
Read the full narrative on Nutex Health (it's free!)
Nutex Health's narrative projects $1.1 billion revenue and $220.9 million earnings by 2029.
Uncover how Nutex Health's forecasts yield a $266.40 fair value, a 42% upside to its current price.
While new sites like West Little Rock support the growth story, the most pessimistic analysts warn that Nutex’s heavy arbitration dependence could cap value, even if revenue reaches about US$1.0 billion and earnings about US$216.9 million by 2029, so it is worth weighing this against more optimistic views that may be revised after this expansion.
Explore 6 other fair value estimates on Nutex Health - why the stock might be worth less than half the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com